Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hellenic Oncology Research Group
With
University Hospital of Crete
Dose dense chemotherapy has been proven beneficial in various oncological settings. It is proposed that this concept be tested in ovarian cancer, with the support of growth factors. It is hypothesized that, if feasible, dose-dense chemotherapy may be more effective.
Age
18–75
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Histologically- or cytologically- confirmed ovarian cancer requiring standard chemotherapy
Patients have to be chemotherapy naive
Patients may have undergone cytoreductive surgery, or this may have been omitted due to dissemination
Age \>18 years.
Performance status (WHO) 0-2
Life expectancy of at least three months.
Adequate bone marrow function (Absolute neutrophil count \>1000/mm\^3, Platelet count\>100000/mm\^3, Hemoglobin\>9gr/mm\^3).
Adequate liver (Bilirubin\<1.5 times upper limit of normal and SGOT/SGPT\<2 times upper limit of normal) and renal function (creatinine\<2mg/dl)
Informed consent
You may not be if
Pregnant or nursing
Psychiatric illness or social situation that would preclude study compliance'
Other concurrent uncontrolled illness
No other invasive malignancy within the past 5 years except nonmelanoma skin cancer
Clareo Health | Paclitaxel and Carboplatin Combination as 1st Line Treatment in Ovarian Carcinomas
